Li et al (2010a, b) demonstrated that treatment of breast cancer cell lines with DNMT inhibitors induced epigenetic reactivation of endogenous estrogen and progesterone receptors (Li et al. 2010b). This evidence concerns the gene DNMT1 and breast carcinoma.